- ►rsmjournals.com B Caldwell, S Aldington, M Weatherall, P … - JRSM, 2006 - jrsm.rsmjournals.com Design: Systematic review and meta-analysis of randomized double-blind clinical
trials of celecoxib of at least 6 weeks' duration and presented data on serious
cardiovascular thromboembolic events. Data sources included six ... Cited by 124 - Related articles - BL Direct - All 13 versions
BCS Aldington, M Weatherall, P Shirtcliffe, R … - JR Soc Med, 2006 - jrsm.co.uk SUMMARY Objectives: To examine whether the increased risk of cardiovascular
events with rofecoxib represents a class effect of cyclooxygenase-2 (COX-2)
specific inhibitors. Design: Systematic review and meta-analysis of ... Related articles - View as HTML - All 9 versions
S Hernández-Dıaz, C Varas-Lorenzo, LA … - Basic Clin Pharmacol Toxicol, 2006 - 213.4.18.135 Abstract: Whether non-aspirin non-steroidal antiinflammatory drugs (NSAIDs)
affect the risk of myocardial infarction is unclear. Also, it is unknown whether
the effect varies by individual NSAIDs. To summarize the evidence from ... Cited by 91 - Related articles - View as HTML - BL Direct - All 9 versions
[CITATION] Cardiovascular safety of CELEBREX: a meta-analysis of 41 clinical studies in 44,308 …
L Simon, W White, T MacDonald, S Pan, R … - American College of Rheumatology (ACR) annual …, 2005 Cited by 11 - Related articles
[CITATION] Drugs Administration CLASS Advisory Committee Briefing Document
- ►nih.gov [PDF] PM Kearney, C Baigent, J Godwin, H Halls, … - British Medical Journal, 2006 - bmj.com You are seeing this message because your web browser does not support basic web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Objective To assess the ... Cited by 446 - Related articles - BL Direct - All 11 versions
- ►ecmaj.com LE Levesque, JM Brophy, B Zhang - Canadian Medical Association Journal, 2006 - ecmaj.com Results: The risk of MI was highest following first-time use of rofecoxib
(adjusted rate ratio [RR] 1.67, 95% confidence interval [CI] 1.21–2.30), with
events occurring within a median of 9 (6–13) days after therapy was ... Cited by 47 - Related articles - BL Direct - All 19 versions
LCC PhD, DMA PhD - pharmacoepidemiology and drug safety, 2007 - ebmctiame.carebmc.net SUMMARY Purpose To evaluate the risk of myocardial infarction (MI) associated
with the use of selective cyclooxygenase-2 (COX-2) inhibitors (coxibs). Methods
Systematic review and meta-analysis of randomised controlled trials (RCTs) ... Cited by 16 - Related articles - View as HTML - BL Direct - All 3 versions
WB White, CR West, JS Borer, PB Gorelick, L … - The American journal of cardiology, 2007 - Elsevier Some nonsteroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2
selective inhibitors, have been associated with increased cardiovascular (CV)
events in recent clinical trials or observational studies. To determine ... Cited by 74 - Related articles - All 13 versions
M Weatherall, S Aldington, P Shirtcliffe, B … - Journal of the New Zealand Medical Association, 2005 - nzma.org.nz On 22 February 2005, Medsafe advised that the increased cardiovascular risk of
cyclooxygenase-2 (COX-2) inhibitors outweighs their benefit for the general
population and recommended that people at high risk of cardiovascular ... Cited by 6 - Related articles - Cached - All 8 versions
